Abstract-Hypoxia is a consequence of the decrease in the oxygen reaching the tissues of the body. It is a prominent feature of most solid tumors and is known to promote malignant progression, metastatic capacity, resistance to chemotherapy, and leads to poor patient prognosis. When a cell is under hypoxic stress, a cascade of cell signals is initiated through a family of transcription factors named as hypoxia inducible factors (HIFs). During hypoxia, HIF stabilizes and enters the nucleus and binds to the DNA via the hypoxia response element (HRE) and leads to the translation of downstream genes. The decision of adaptation or cell death depends on the extent of hypoxic stress faced by the cells. Proper understanding of hypoxic stress response is critical for understanding the mechanism of tumor cell adaptation to hypoxia and to develop efficient therapeutic interventions. In this paper, we develop a Boolean network model with targeted drug intervention in a cell that mimics persistent hypoxia. This hypoxic pathway is combined with pathways that help the cell adapt to the situation or undergo cell death. It is linked to apoptosis, cell survival, and energy production via the p53/Mdm2, PI3k/Akt/mTOR, and Glycolysis/TCA cycle pathways, respectively. In this model, we have incorporated eight known anticancer drugs that target these pathways. Through simulations, we have identified drug combinations that provided overall benefits to the cell in comparison to the no intervention case. Where applicable, the behavior predicted by this model is in agreement with experimental observations from the published literature.
cell faces hypoxic stress due to normal physiological variations during fetal development, wound healing, adapting to a high altitude, inflammation, etc. [2] . Different cells in the body have different partial pressures of oxygen that are considered to be normal, and a drop in the partial pressure of oxygen below these normal levels creates a hypoxic condition. The difference of the partial pressures of oxygen between the blood and the mitochondria of the cells is responsible for the transfer of oxygen between blood and all the cells in the body. This intracellular pressure of oxygen PO 2 is measured by three hydroxylases. These hydroxylases are named as prolyl hydroxylase domain (PHD) containing proteins, namely PHD1, PHD2, and PHD3 [2] . During hypoxia, the oxygen required for PHD2 functioning is diminished and PHD2 is inhibited. This results in the activation of the hypoxia inducible factor (HIF) signaling cascade. HIF is a heterodimer comprising of α and β subunits. HIFα consists of three subunits, HIF-1α, HIF-2α, and HIF-3α.The HIFβ subunit consists of three subunits as well, HIF-1β, HIF-2β, and HIF-3β [3] . The concentration of oxygen in the cells regulates the HIF-1α subunit, but the HIF-1β subunit is unaffected by the oxygen levels. HIF-1α quickly stabilizes and is accumulated under hypoxic conditions by the inhibition of PHD2, but on reoxygenation, it is suddenly destroyed and its half-life is less than 5 min [4] . This short half-life shows that HIF-1α accumulation is not good for the body. HIF-1α undergoes hydroxylation by PHD2 [5] , which increases its interaction with the tumor suppressor protein, pVHL, the von-Hippel Lindau tumor suppressor protein which marks HIF-1α for degradation with the help of E3 ubiquitin ligase [6] . PHD2 requires oxygen, iron, α-ketoglutarate (αKG), and ascorbate as substrates to function properly. Oxygen and αKG are the cosubstrates required for PHD2 functioning, whereas ascorbate and Fe 2+ (iron) are the cofactors required for PHD2 functioning. During hypoxia, the substrate oxygen required for PHD2 functioning is not available and, hence, PHD2 is inhibited. This results in the activation and stabilization of HIF-1α subunit which enters into the nucleus and binds with HIF-1β subunit to form the HIF heterodimer [6] , which is a transcription factor. This HIF transcription factor binds to the hypoxia responsive elements (HRE) of the target genes and this interaction drives the transcription in a hypoxia responsive manner.
Energy production in cells takes place through two major pathways: aerobic metabolism which occurs when oxygen is available, and anaerobic metabolism which occurs when oxygen is deficient. Aerobic metabolism is also known as tricarboxylic acid cycle (TCA cycle), and anaerobic metabolism is also known as Glycolysis. Almost 95% of the oxygen that we breathe in is used up by the reactions of the electron transport chain (ETC), which is the last stage in the TCA cycle, to produce energy as adenosine triphosphate (ATP). A proton gradient is created across the innermost mitochondrial membrane as a result of redox reactions taking place in the mitochondrial ETC, due to the transfer of electrons from an electron donor to the terminal electron acceptor oxygen. The proton gradient generated across the mitochondrial membrane pumps protons which converts adenosine diphosphate to ATP. However, some of the electrons will not be transferred from the electron donor forming reactive oxygen species (ROS) such as superoxide that creates oxidative stress [7] . During hypoxia, the ETC is inhibited since there is not enough oxygen available, which generates even more ROS thereby accentuating oxidative stress [8] . This oxidative stress does not allow iron to cycle between the different oxidation states which results in PHD2 inhibition. Oxygen consumption is thus coupled to release of energy in the form of ATP, which is essential for the proper functioning of the cell. In hypoxic conditions, cells switch from TCA cycle to glycolysis as the main source of energy production. Pyruvate dehydrogenase kinase (PDK), a hypoxia target gene, inhibits the conversion of pyruvate to acetyl-coenzyme A (AcCoA). AcCoA is a precursor for TCA cycle to produce ATP. This pyruvate in turn increases the rate of glycolysis as well as suppresses PHD2 which increases translation of HIF-1α. Hence, low oxygen tension should be identified and proper adaptation measures should be taken by the cell for survival.
In normal tissues, the oxygen supply will depend on the metabolic requirements [9] . However, in tumors, the oxygen requirement is way higher than the supply and this leads to some areas in the tissue where there is inadequate oxygen. This energy demand makes oxygen become a limiting factor. As the tumor grows to about 2-3 mm in diameter, the normal oxygen supply is unable to meet the increased energy demand of cancer tissues. Tumor cells that are beyond the diffusion distance for oxygen (>70 μm) are exposed to low levels of oxygen. The cells adapt to this scarcity of oxygen by creating new blood vessels from the already existing blood vessels (tumor angiogenesis) and also by increasing the glycolytic flux for easy and faster anaerobic energy production. Moreover, an adaptive response is mounted through recruiting enzymes, transcription factors, and via triggering specific protein signaling cascades. Furthermore, HIF functions as a master regulator of cellular and systemic homeostatic response to hypoxia through activating transcription of several genes including those involved in energy metabolism, angiogenesis, apoptosis, and other genes whose protein products increase the oxygen delivery or facilitate metabolic adaptation to hypoxia. HIF activates the transcription of genes that are involved in crucial aspects of cancer biology including angiogenesis, cell survival, glucose metabolism, and invasion [10] .
Increased levels of hypoxia are consistently correlated with genetic instability, tumor progression, and poor patient prognosis [11] . The identification of targets that mediate response in the hypoxic cell in response to hypoxia is important because inhibition of these targets could lead to cell death. One of the hallmarks of cancer is a metabolic switch from the TCA cycle (aerobic) to Glycolysis (anaerobic) as a main source of energy production [12] , even when adequate oxygen is available. This is known as the Warburg effect and was observed by O. Warburg in the 1920s. Warburg effect is the observation that most cancer cells predominantly produce energy by a high rate of glycolysis followed by lactic acid fermentation in the cytosol, rather than by a comparatively low rate of glycolysis followed by oxidation of pyruvate in mitochondria as in most normal cells. The main oxygen-responsive signaling pathways that mediate cellular response to hypoxia involve the HIF family of transcription factors, unfolded protein response (UPR), and mammalian target of rapamycin (mTOR) [13] . In conditions of severe hypoxia, HIF is activated and leads to the regulation of HIF family of transcription factors which includes VEGF (angiogenesis), GLUT1 (glucose transporter), and almost all enzymes involved in glycolysis. Severe hypoxia also leads to mistakes in protein folding, which contributes to endoplasmic reticulum (ER) stress or UPR. During UPR, the cell tries to conserve energy by stopping translation of proteins and directs all misfolded proteins to undergo degradation in the ER. One of the pathways through which UPR is mediated is through the PERK pathway. Hypoxia also causes a drop in ATP levels which mediates a response through the mTOR pathway. Metabolic reprogramming in tumor cells is in part mediated by HIF and mTOR. But this switch is also regulated by p53 and PI3K/Akt pathways as well. The downstream effects of these mediate apoptotic or cell-survival regulators. There is a lot of published literature that discusses the importance of hypoxia in cancer biology. It has been long recognized that therapeutically targeting hypoxia might alleviate some of the negative characteristics associated with cancer cells.
In this paper, we develop a Boolean network (BN) model consistent with hypoxia stress response pathway information from the biological literature. To this, we integrate major pathways involved in adaptation in a hypoxic cell and consider targeted therapy in these pathways to up-regulate the average apoptotic activity and down-regulate both the average cell-survival activity and average energy production through fermentation. This paper is organized as follows. Section II introduces the basic concepts of stress response pathways. Section III discusses the idea of BN modeling and models the hypoxia stress response pathways. Section IV provides the literature validation of hypoxia stress response pathways. Section V considers the use of the BN model for coming up with targeted combination therapies for counteracting the negative effects of hypoxia. Finally, Section VI compares the results with the available experimental ones from the published literature.
II. STRESS RESPONSE PATHWAYS
In biology, almost all the prior knowledge and information is usually available as signaling pathways. This information is unable to represent the multivariate interactions between the genes, even though it can give a pictorial representation of the univariate interactions. It is also possible that two or more pathways can share the same genes or the same node. Thus, a biological pathway gives a clear cut idea of the marginal relationship between different genes in that pathway, but fails to provide information about how these genes interact globally when they are present in different pathways. The main aim of this paper is to generate a BN whose state transitions realize the hypoxic stress response pathways. The resulting BN obtained shows dynamic behavior which is consistent with the experimental results and observations from the published literature [1] , [14] . By incorporating the expert knowledge obtained from the biological pathways, the cardinality of the search space of the network can be reduced. Layek, Datta, and Dougherty [15] have provided a discussion on the state space and a reduction in cardinality of this state space with expert biological knowledge. The main drawback of the pathway knowledge is that it provides only partial information and that too restricted to a specific context. By mathematically modeling the multivariate interaction between the genes in a pathway, these networks can be used to differentiate between normal cell behavior and diseased cell behavior. By working with the genetic regulatory networks instead of the biological pathways, the holistic behavior of the genes can be captured and the appropriate therapeutic interventions can be developed. The aim of biological pathway modeling is to marginally capture the causal interactions taking place inside a cell when a stimulus or stress is applied. Stress response pathways constitute an important set of pathways studied in the biological literature. The main aim of adaptive stress response pathways is to understand the transcription of cytoprotective genes in the presence of stress [16] . If a stress is applied to a cell exogenously such as xenobiotic, radiation, heat, etc., the cell responds via several highly conserved adaptive stress response pathways that will try to attenuate the consequences of this stress and re-establish the homeostasis. The rapid response of the stress response pathways can be attributed to their special architecture. Basic components of this architecture include a transcription factor, a sensor, and a transducer. A schematic diagram of the architecture of the stress response pathways is shown in Fig. 1 [14] .
A transcription factor is a protein which binds to the DNA through the response elements within its promoter region and, thus, activates or up-regulates the expression of the target genes. During the absence of stress, the transcription factor is prevented from entering into the nucleus with the help of a protein known as a sensor. It interacts with the transcription factor in such a way that the transcription factor is sequestered in the cytoplasm. When a cell is faced by a stress, an enzymatic protein, called a transducer, transfers a cue from a pathway which lies upstream of the sensor/transcription factor complex. The transducer either modifies the transcription factor or modifies the sensor which destabilizes the sensor/transcription factor complex. The activated transcription factor then enters the nucleus and is able to up-regulate the target genes. 
III. BOOLEAN NETWORK MODELING
The expression of each gene is quantized to two levels, and each node x i represents the state/expression of the gene i, where x i = 0 means that gene i is OFF and x i = 1 means that gene i is ON. The function f i is called the predictor function for gene i . Updating the states of all genes in Υ is done synchronously at every time step according to their predictor functions. At time t, the network state is given by x(t) = (x 1 (t), x 2 (t), . . . , x n (t)), which is also called the gene activity profile of the network. The prior biological knowledge of the hypoxia stress response pathways is used to arrive at the BN describing hypoxia stress response activity. The Karnaugh map (K-map) reduction technique is used to obtain an update equation for each and every node [14] , [15] . The hypoxia stress response pathway in human cells is shown below in Fig. 2 .
The pathway segments from the pathways in Fig. 2 are given by:
From the pathway segments described in (1)- (10), and applying the technique of K-map reduction explained [15] , the update equation for each and every gene is obtained. The state space is defined as [PHD2,HIF,HRE,ROS,PDK,PYRUVATE]. From the set of possible BNs, we chose the one that appealed the best to our biological knowledge and the resulting update equations are 
HIF next = PHD2 (13)
ROS next = HIF (15)
This BN will have two different contexts based on the value of the hypoxic stress, i.e., when Hypoxia = 0 and when Hypoxia = 1. The resulting equations are expressed as a digital circuit and shown in Fig. 3 . The state transition diagrams resulting from (11)-(17) for the two cases, Hypoxia = 0 and Hypoxia = 1, are shown in Figs. 4 and 5, respectively. In these transition diagrams, the genes in the binary state representation are ordered as [PHD2, HIF, HRE, ROS, PDK, PYRUVATE], and the binary states are compactly represented by their decimal equivalents. For instance, the binary state (111 100) would be represented by the decimal number 60. The states of particular interest are the attractors as they give rise to the steady-state properties of the network. In Fig. 4 , the state of interest is the singleton attractor 32 (100 000). On the other hand, in Fig. 5 , the state space is partitioned. Hence, the final attractor cycle will depend on the starting state, one of them
Spurious attractors of this type do arise in BN modeling. When such networks are derived from pathway information, the ill-posed nature of the inverse problem makes the appearance of spurious attractors even more likely. The equations derived were simulated using MATLAB by giving an external stress input signal for a duration of 100 time steps, and both the input signal and the responses are shown in Figs. 6 and 7. From the plot in Fig. 7 , one can reasonably expect to see oscillations in the presence of hypoxic stress similar to the p53-MDM2 oscillations induced by DNA damage. It would be interesting to experimentally verify if this is indeed the case. In Fig. 7 , the two time responses correspond to the two steady-state attractor cycles as shown in Fig. 5 .
IV. LITERATURE VALIDATION OF THE HYPOXIA STRESS RESPONSE MODEL
Nguyen et al. [17] show that the optimal HIF-1α transcriptional activity requires sequential inhibition of PHD2. They demonstrate the stabilization of HIF-1α at 3% of oxygen and higher stabilization at 1% of oxygen in human embryonic kidney cells. At 21% of oxygen concentration, that is during normoxia, there was no HIF-1α stabilization, which shows that HIF-1α stabilizes only during low oxygen tension. Nguyen et al. [17] experimentally validates HIF-1α stabilization when PHD2 is inhibited. Qutub and Popel [18] present an experimental-based computational method that shows the in-phase relationship between ROS and HIF-1α. Therapeutic agents target five compounds that are involved in HIF-1α hydroxylation, i.e., iron (Fe), ascorbate (Asc), hydrogen peroxide (H 2 O 2 ), 2-oxaloglutarate (2-OG) and succinate. The net effect is that PHD2 action is inhibited and HIF-1α is stabilized. ROS affects HIF-1α hydroxylation by changing H 2 O 2 , Fe 2+ , ascorbate, 2-OG, and succinate. In the normal conditions, when Fe 2+ and ascorbate were upregulated, HIF-1α reached its peak value within an hour. Next, when ROS production was increased by tenfold by decreasing Fe 2+ and ascorbate concentrations, it led to a fivefold increase in the maximum HIF-1α expression. This clearly explains that ROS and HIF-1α are in phase. Thus, this paper experimentally validates the in-phase relationship between HIF-1α and ROS. Chandel et al. experimentally validate that hypoxia activates the transcription of several hypoxia target genes by increasing ROS concentration [19] . They depleted cells of mitochondrial (11)- (17) using digital logic gates. We have also indicated the names of the logic gates used. DNA and showed that if they were then exposed to hypoxia, they did not display any HIF-1α DNA binding activity. This paper experimentally validates that mitochondria are very much essential for the transcriptional activity of hypoxia. Kim et al. experimentally validated that the glycolytic enzymes, which are the hypoxia target genes, are very important for the metabolic adaptation to hypoxia by increasing the conversion of glucose to pyruvate and, finally, the accumulation of lactate. They observed that HIF-1α null mouse embryo fibroblasts failed to upregulate PDK1. This shows that PDK1 is a direct hypoxia target gene, i.e., there is an in-phase relationship between HRE and PDK1 [20] .
V. BOOLEAN MODEL AND TARGETED THERAPY UNDER PERSISTENT HYPOXIA
We model a cell with persistent hypoxia to mimic an unfavorable situation for the system. Under such a situation, the cell may adapt to the hypoxic stress or undergo cell death. To incorporate this adaptation, we include major pathways affected by HIF factors, which can influence cell decisions for adaptation or cell death. The pathways considered are PI3K/Akt/mTOR and metabolic pathways. The PI3K/Akt/mTOR pathway is an intracellular signaling pathway important in regulating the cell cycle. It is directly related to cellular quiescence, proliferation, cancer, and longevity. Metabolic pathways are responsible for the energy production in the cells either through glycolysis or the TCA cycle. We used published results in the literature to get all the necessary pathway information for the model [13] , [21] [22] [23] . Once the pathway information was obtained, anticancer drugs known to act in these pathways were chosen from the literature. The drugs were chosen from the regularly used ones for therapy. It is possible we might have missed out certain drugs, however those can be easily incorporated into the current model as needed. A BN model of all the factors affecting these pathways along with the drug intervention points is modeled. All possible drug combinations were simulated, time evolution of the states of the network (expression levels of genes) was computed, and overall benefit for each drug combination was evaluated. Overall benefit is evaluated in terms of three quantities: 1) upregulation of average activity of Bad (Bcl-2 associated death promoter) gene; 2) down-regulation of average activity of Bcl-2 (B-cell CLL/lymphoma 2) gene; 3) up-regulation of ATP production through TCA/Krebs cycle and down-regulation of ATP produced through glycolysis. The benefit was calculated as the weighted sum of these quantities. The weightage for The reason behind choosing this as a measure of benefit is that Bad is known to promote apoptosis, while Bcl2 is antiapoptotic. We need ATP for cell functioning, however we want it to be produced through the TCA cycle rather than through glycolysis which is the reverse of what happens in cancer (Warburg effect). In a situation where we have persistent hypoxia, we want the apoptotic factors to be up-regulated and energy production to occur through the TCA cycle.
A. Description of Drugs
There are eight drugs used in this simulation. The chosen drugs were selected on the basis of their capability to intervene in the Boolean model. We include a brief description of each. 1) Metformin: An antidiabetic drug suspected to have antitumor properties. In the pathway, it is shown to activate AMPK. 2) Dorsomorphin: A cell-permeable pyrrazolopyrimidine compound that inhibits AMPK kinase activity.
3) Dimethyloxalylglycine: Dimethyloxalylglycine is a cell permeable prolyl-4-hydroxylase inhibitor, which upregulates HIF-1α by suppressing the activity of prolylhydroxylase. 4) Echinomycin: Echinomycin is a peptide antibiotic. It intercalates into DNA at two specific sites, thereby blocking the binding sites of HIF-1α. 5) Avastin: Bevacizumab (trade name Avastin, Genentech/Roche) is an angiogenesis inhibitor, a drug that slows the growth of new blood vessels. It is licensed to treat various cancers, including colorectal, lung, breast (outside the USA), glioblastoma (USA only), kidney, and ovarian. 6) Potassium dichloroacetate: Salts of DCA have been studied as potential drugs because they inhibit the enzyme PDK. 7) Bromopyruvic acid: It is an inhibitor of hexokinase which is an enzyme involved in the first step of glycolysis. L(+)-lactate dehydrogenase and derails the entire gluconeogenic pathway. The major pathways along with the drugs (in green rectangular boxes) that act on these pathways are shown in Fig. 8 . We have used the following abbreviations: Potassium dichloroacetate (PDC); Bromopyruvic Acid (BA); Sodium Oxamate (SO); Dimethyloxalylglycine (DMOG). We did not abbreviate the name of the drugs Metformin, Dorsomorphin, Echinomycin, Avastin. We modeled the pathways in Fig. 8 as a Boolean model to simulate the effects of the various drugs.
B. Simulation Results
We have eight drugs and this corresponds to 2 8 = 256 combinations. We, however, ignore the combinations where Metformin (AMPK activator) and Dorsomorphin (AMPK inhibitor) are both present so that eliminates 64 drug combinations, this leaves us with 192 (=256−64) combinations. As mentioned earlier, the effective drug combination is defined as one which provides the maximum benefit. We will choose a starting state that is unfavorable to the system and determine the cocktail of drugs which provides maximum benefit. Let the starting state correspond to Hypoxia = 1 (always 1 persistent hypoxia), ROS = 1, GF = 1, GFBP = 0, Lactate = 1, VEGF = 1, Bad = 0, Bcl2 = 1. We will assume random states for the other variables in the system. For a given drug combination, we simulate the system from a given random starting condition for 100 time steps. All these results were used to calculate the benefit parameter based on (18) . The procedure was repeated for the same drug combination from 1000 random starting states and the average of the benefit parameter calculated and reported as the benefit of using that specific drug combination. The overall benefit is reported in arbitrary units since we are measuring the expression of the system on a binary scale. In Table I , we identify the combinations of two or three drugs that are effective in tackling the problem. We are not reporting cocktails having more drugs in an effort to constrain the possible side effects of treatment. The Initialize drug combination i of system 6:
for j=1:n do Network State 7:
Initialize random starting state j of system 8:
for k=1:m do Time-steps 9:
Update state of system based on Boolean model 10:
Save the state transitions 11:
end for 12:
Calculate benefit for state j on equation (18) 13: end for 14:
Calculate benefit for drug combination g 15: end for binary status of each drug is shown in the table as well. Here, 1 indicates that the drug is being applied, and 0 indicates that the drug is not being applied. It is to be noted that the combinations reported here are only a subset of all possible combinations. The drug combinations with benefit greater than the situation with no intervention are shown in green. Some combinations which have lower benefit are shown in red. The pseudocode of our simulation is shown in Algorithm 1.
VI. DISCUSSION
It has been experimentally observed that inhibiting HIF-1α alone may not be sufficient to halt angiogenesis and tumor growth. Hence, HIF-1α inhibitor needs to be used in combination with other drugs that are unfavorable to the tumor microenvironment [24] . Epithelial to mesenchymal transition (EMT) is an important feature of carcinogenesis and Dorsomorphin has been shown to reverse the mesenchymal phenotype [25] , [26] . It is also a known inhibitor of bone morphologic proteins whose role in cancer is contested as pro-or antitumor, but are known to induce angiogenesis [27] , [28] . DMOG indirectly activates HIF-1α by inhibiting PHD's and stabilizing HIF-1α. It is also known to up-regulate VEGF, GLUT1; however, it does not increase mRNA levels of HIF-1α [29] , [30] . Fannale et al. were able to experimentally validate that hypoxia negatively regulates breast cancer cell growth during short term in vitro exposure [31] , this can be achieved by adding DMOG to stabilize HIF-1α. They also noticed that it led to changes in DNA damage repair pathways which can induce apoptosis or necrosis. Since DMOG up-regulates GLUT1 which increases uptake of glucose [30] , this can be counteracted by adding BA and SO [32] , [33] . Our results suggest that using these drugs in combination will prevent angiogenesis and since Dorsomorphin also affects AMPK it will also down-regulate PI3K/Akt pathways. Antiangiogenesis therapy has shed new light for cancer treatment but its effectiveness is still not completely validated [34] . It has been experimentally validated that glycolysis inhibitors aid the anti-VEGF treatment of Avastin in coloretal cancer [34] . One reason for this evidence points to the fact that one outcome of hypoxic environment is resistance to Avastin. In [34] , they use BA (Hexokinase II inhibitior) in combination with Avastin to get favorable outcome in terms of tumor volume and survival. Our Boolean model predicts that this drug combination along with Dorsomorphin (BA+Avastin+Dorsomorphin) or just Dorsomorphin with BA leads to favorable outcomes. Additionally, we also see that Avastin in combination with Sodium oxamate and Dorsomorphin will also be an effective combination. Sodium Oxamate is known to be an inhibitor of glycolysis [35] , [36] . It was also seen that Avastin by itself will not lead to favorable outcomes as compared to using it with other drugs in combination [37] . Dicholoroacetate is used for cancer therapy as a suppressor of the Warburg effect [38] . It is one of the characteristics of cancer cells, whereby they use Glycolysis (even in presence of oxygen) to meet the majority of their energy needs. Dichloroacetate works by inhibiting the enzyme PDK, increases the flux of pyruvate into the mitochondria, and promoting glucose oxidation over glycolysis. This reverses the suppressed mitochondrial influenced apoptosis in cancer and results in suppression of tumour growth in vitro and in vivo [38] . Epidemiological studies of Metformin, an antidiabetic drug have suggested that it has anticancer properties. Table I does have any drug combination that has Metformin in the drug cocktail. Simulations with Metformin in combination with other drugs yielded conflicting results. By conflicting results we mean that the response was better by treating with Metformin in some cases and opposite in some other cases. All the drug combinations shown in Table I without Metformin in the combination gave a positive effect on treatment for the different starting conditions. We made a literature survey to check this ambiguity. We found that current preclinical and clinical knowledge suggests that patients exhibiting hyperinsulinemia and tumors expressing insulin receptor LKB1 and TSC2 would only benefit from metformin but not others with normal insulin levels and tumors lacking expression of insulin receptor (INSR) LKB1 and TSC2 [39] . The gene LKB1 was not a part of the BN model presented, it is brought into discussion due to the role it plays in activating AMPK. Metformin also acts to activate AMPK and inhibit mTOR. So LKB1 upregulated in a Boolean model implies that AMPK is also up-regulated. However, the direct insulin-independent effects of metformin originate from LKB1-mediated activation of AMPK and a reduction in mTOR signaling and protein synthesis in cancer cells. So the gene LKB1 was used to emphasize one of the mechanisms through which Metformin acts to suppress mTOR. It has also been experimentally validated that Metformin's actions varies based on the level of glucose. A recently published work [40] suggests that clinical trials of Metformin have yielded conflicting results, thereby further complicating the issue. Some studies point to AMPK as a tumor suppressor, whereas others seem to suggest that it can be a promoter of tumor growth. Our model predicts newer drug combinations with which to treat cancer, which might be required since cancer cells have the ability to bypass blockades using alternative pathways. By blocking multiple pathways, we hope to drive the system into a state which increases apoptosis or reduces proliferation. We are encouraged at this point that the predictions made by our model are supported by data from the real world.
VII. CONCLUDING REMARKS
Cancer cells are known to thrive in altered microenvironmental niches, including in a hypoxic niche. We have investigated via simulations the dynamics and response of cells to hypoxia, while also incorporating other major pathways that may be altered at hypoxic stages. The biological pathways involved in cell growth and metabolic regulation were mapped to a BN. The equivalent digital circuit was used to identify drug combinations that may be most effective in reducing the negative effects of hypoxia while giving maximum advantage. We incorporated the drug intervention points into our model allowing us to test different combination therapies in terms of their efficacy in mitigating the effects of faults in the network. The predictions from the current model we developed to ameliorate hypoxia-based tumor aggressiveness is encouraging, in the sense that it agrees with several of the drugs used in current cancer therapy. We, however, need to proceed with caution as some of the drug combinations suggested here may still fail to work. This may be due to cross talk with other pathways, feedback loops, and other molecules directly influencing the pathways in question and other mutations that might be present. Nevertheless, this is a good starting point where there is agreement between theoretical simulation, albeit literature-based and real world. We believe this can help us fast track to test optimal intervention techniques, down the road.
